MARLBOROUGH, Mass., Aug. 31, 2017 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage RNAi company developing innovative therapeutics that address significant unmet medical needs, announced today that Dr. Geert Cauwenbergh, RXi's President and CEO, will present at the 8th Annual Investing for Cures Forum hosted by Landmark Angels.
Date: Thursday, September 7, 2017
Time: 9:15 a.m. ET
Location: Club 101, 101 Park Avenue, New York City, NY
The presentation will be available under the "Investors – Events and Presentations" section of the Company's website, www.rxipharma.com, approximately 1 hour following the presentation.
RXi's Next Generation Therapeutic Platform: sd-rxRNA®
A successful RNAi therapeutic platform includes stable, specific and potent RNAi compounds and the ability to deliver these compounds to the tissue(s) of interest. Scientists at RXi have developed proprietary compounds in which drug-like properties are built into the RNAi compound itself. These novel compounds are termed 'self-delivering' RNAi compounds or sd-rxRNA. RXI-109, a potent anti-fibrotic agent, was developed based on the novel chemistry of the sd-rxRNA platform. RXI-109 is designed to reduce the expression of CTGF, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin and eye. RXI-109 first entered clinicals trial in June 2012.
RXi's development pipeline also includes sd-rxRNA compounds for immunotherapy to treat cancer. Our approach to immunotherapy builds on well-established methodologies of adoptive cell transfer. Immune cells, such as T-lymphocytes, are isolated from specific patients or retrieved from allogeneic immune cell banks, and then expanded and possibly processed to express tumor-binding receptors. Our method introduces sd-rxRNA compounds directed against immunosuppressive targets as a new and important step in ex-vivo processing of the immune cells. This step eliminates the expression of immunosuppressive receptors or proteins from the therapeutic immune cells, making them less sensitive to tumor resistance mechanisms and thus improving their ability to destroy the tumor cells.
RXi has recently advanced its immunotherapy pipeline with the selection of two self-delivering RNAi (sd-rxRNA®) compounds for preclinical development. For oncology treatments based on adoptive cell transfer (ACT), sd-rxRNA compounds RXI-762 and RXI-804 suppress the expression of immune checkpoint proteins PD-1 and TIGIT respectively, which may result in an improved efficacy to the targeted tumors. This decision triggered the selection of a manufacturing facility to initiate production of cGMP grade material, initially for the first of these two compounds (RXI-762). The latter also supports moving RXI-762 into clinical development as early as 2018 as part of an ACT therapy.
About RXi Pharmaceuticals
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a clinical-stage company developing innovative therapeutics that address significant unmet medical needs. Building on the pioneering discovery of RNAi, scientists at RXi have harnessed the naturally occurring RNAi process which can be used to "silence" or down-regulate the expression of a specific gene that may be overexpressed in a disease condition. RXi developed a robust RNAi therapeutic platform, including self-delivering RNA (sd-rxRNA®) compounds, that have the ability to highly selectively block the expression of any target in the genome, thus providing applicability to many therapeutic areas. Our current programs include dermatology, ophthalmology, and cell-based immunotherapy. RXi's extensive patent portfolio provides for multiple product and business development opportunities across a broad spectrum of therapeutic areas, and we actively pursue research collaborations, partnering and out-licensing opportunities with academia and pharmaceutical companies. For additional information, visit the Company's website, www.rxipharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about: our ability to successfully develop RXI-109, Samcyprone™ and our other product candidates (collectively "our product candidates"); the future success of our clinical trials with our product candidates; the timing for the commencement and completion of clinical trials; our ability to enter into strategic partnerships and the future success of these strategic partnerships; and our ability to deploy our sd-rxRNA® technology through partnerships, as well as the prospects of these partnerships to provide positive returns. Forward-looking statements about expectations and development plans of RXi's product candidates and partnerships involve significant risks and uncertainties, including the following: risks that we may not be able to successfully develop and commercialize our product candidates; risks that product development and clinical studies may be delayed, not proceed as planned and/or be subject to significant cost over-runs; risks related to the development and commercialization of products by competitors; risks related to our ability to control the timing and terms of collaborations with third parties; and risks that other companies or organizations may assert patent rights preventing us from developing or commercializing our product candidates. Additional risks are detailed in our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors." Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. RXi does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release.
RXi Pharmaceuticals Corporation
SOURCE RXi Pharmaceuticals Corporation